Here are four tings to know.
1. The drugmaker will eliminate about 3,500 positions globally, which will generate roughly $500 million in annual savings.
2. Most of the job cuts will come from a voluntary early-retirement program Eli Lilly is offering U.S. employees.
3. The drugmaker will also close a drug plant in Iowa, along with its research and development offices in New Jersey and China.
4. The layoffs follow a challenging year for Eli Lilly, which has encountered several major development setbacks for its experimental rheumatoid arthritis drug baricitinib and its Alzheimer’s treatment solanezumab.
More articles on supply chain:
Novo Nordisk settles diabetes drug lawsuit for $58.7M: 3 things to know
Supply chain tip of the day: Consider seasonal indexes when demand planning
Patient death spurs FDA to halt cancer drug trials
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
